AlphaCrest Capital Management LLC boosted its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL – Get Rating) by 186.0% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,887 shares of the company’s stock after purchasing an additional 5,129 shares during the quarter. AlphaCrest Capital Management LLC’s holdings in Omnicell were worth $686,000 at the end of the most recent quarter.
Other institutional investors also recently made changes to their positions in the company. Wipfli Financial Advisors LLC bought a new stake in shares of Omnicell in the third quarter worth $25,000. Money Concepts Capital Corp acquired a new stake in shares of Omnicell in the 3rd quarter valued at about $27,000. Van ECK Associates Corp bought a new position in shares of Omnicell during the third quarter worth about $49,000. UMB Bank n.a. grew its stake in Omnicell by 28.5% in the third quarter. UMB Bank n.a. now owns 721 shares of the company’s stock worth $63,000 after purchasing an additional 160 shares in the last quarter. Finally, CoreCap Advisors LLC bought a new stake in Omnicell in the second quarter valued at about $101,000.
Omnicell Stock Performance
OMCL opened at $53.70 on Wednesday. Omnicell, Inc. has a twelve month low of $46.11 and a twelve month high of $138.50. The stock has a market cap of $2.42 billion, a PE ratio of 537.00, a price-to-earnings-growth ratio of 5.48 and a beta of 0.89. The business’s 50 day moving average is $54.59 and its 200-day moving average is $66.21. The company has a current ratio of 2.06, a quick ratio of 1.71 and a debt-to-equity ratio of 0.50.
Analyst Ratings Changes
Insider Buying and Selling at Omnicell
In other Omnicell news, EVP Scott Peter Seidelmann sold 4,436 shares of the business’s stock in a transaction on Friday, December 16th. The stock was sold at an average price of $47.79, for a total transaction of $211,996.44. Following the completion of the transaction, the executive vice president now owns 30,733 shares in the company, valued at approximately $1,468,730.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.76% of the stock is owned by company insiders.
Omnicell, Inc engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation.
- Get a free copy of the StockNews.com research report on Omnicell (OMCL)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL – Get Rating).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.